Recombinant Mouse Anti-CD28 Antibody (5.11A1) (CAT#: PABX-031)

Figure 1 Activation of T cell hybridoma cells via superagonistic CD28-specific mAb.

The 58 T cell hybridoma line supplemented with a rat TCR was retrovirally transduced with mouse CD28 containing the following replacements: (A) the whole extracellular part of rat CD28, (B) the rat C′′D loop, or (C) the human C′′D loop. The cell lines were left unstimulated or were stimulated via immobilized anti-TCR mAb R73, superagonistic CD28-specific mAb (JJ316 for rat, 5.11A1 for human) at the indicated final concentrations, ranging from 10 to 1 μg/ml, or conventional CD28-specific mAb (JJ319 for rat, 37.51 for the chimeric molecules). After 2 d, supernatants were tested for the presence of mouse IL-2 by ELISA. Because stimulation with conventional CD28-specific mAb did not result in substantial IL-2 production at any concentration tested, only results using the highest concentration (10 μg/ml) are presented. One of at least three independent experiments with similar results is shown.

Lühder, F., Huang, Y., Dennehy, K. M., Guntermann, C., Müller, I., Winkler, E., ... & Hünig, T. (2003). Topological requirements and signaling properties of T cell–activating, anti-CD28 antibody superagonists. Journal of Experimental Medicine, 197(8), 955-966.

Figure 2 Activation markers, proliferation and cytokine release from human T cells in response to dry-coated anti-CD28 dAb-002.

Human T cells were added to wells coated with varying concentrations of Vκ dummy dAb, dAb-002, or the superagonist Ab mAb 5.11A1 and cell activation determined by increased expression of the activation Ags CD69 (A) cytokine release. The concentration of dAb or mAb 5.11A1 added to each well for dry-coating is indicated in (A). Data are mean ± SD of 10 different blood donors.

Suchard, S. J., Davis, P. M., Kansal, S., Stetsko, D. K., Brosius, R., Tamura, J., ... & Yang, Z. (2013). A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety. The Journal of Immunology, 191(9), 4599-4610.